Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2519-2526

  Mohanam, Sanjeeva ^a   Jasti, Sushma L ^b   Kondraganti, Sudha R ^b   Chandrasekar, Nirmala ^a   Kin, Yoshiaki ^b   Fuller, Gregory N ^b   Lakka, Sajani S ^a   Kyritsis, Athanassios P ^b   Dinh, Dzung H ^a   Olivero, William C ^a   Gujrati, Meena ^a   Yung, W K A ^b   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INFILTRATION; CANCER INVASION; EXTRACELLULAR MATRIX; FETUS; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; RECEPTOR BINDING;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN; DNA, ANTISENSE; FIBRIN; GENE THERAPY; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NEOPLASM INVASIVENESS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034885886     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. The urokinase-type plasminogen activator system in cancer metastasis: A review
2. The role of the plasminogen activation system in cancer
3. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model
4. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor
5. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis
6. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity
7. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β
8. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction
9. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals
10. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice
11. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system
12. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms
13. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor
14. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87)
15. Migratory patterns of lac-z transfected human glioma cells in the rat brain
16. Glioma invasion in the central nervous system
17. Urokinase induces receptor mediated brain tumor cell migration and invasion
18. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma
19. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo
20. Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression
21. Prognostic significance of proteolytic enzymes in human brain tumors
22. Prognostic role of urokinase-type plasminogen activator in human gliomas
23. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse
24. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model
25. Prevention of metastasis by inhibition of the urokinase receptor
26. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade
27. Antisense inhibition of urokinase: Effect on malignancy in a human osteosarcoma cell line
28. A human β-actin expression vector system directs high-level accumulation of antisense transcripts
29. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor
30. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody
31. Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain
32. Glioma cell invasion visualized by scanning confocal laser microscopy in an in vitro co-culture system
33. Invasive pattern of lac-Z-transfected human glioblastoma cells in nude mice brain
34. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule
35. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
36. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours
37. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness
38. Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion
39. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428
40. Urokinase induces proliferation of human ovarian cancer cells: Characterization of structural elements required for growth factor function
41. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice
42. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: In vitro and in vivo studies of uptake, effects and toxicity
43. Invasion by esophageal cancer cells: Functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor